He will also participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13 titled, "Achieving ...

Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.

Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a Notice of Compliance from Health Canada for its ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...

These products are among the largest oncology biologics expected to lose exclusivity over the next five years.

Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...

Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety ...

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a Notice of ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

Also highlight plans to integrated with Biocon at 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...

Trastuzumab, Nivolumab and Keytruda: Our Bureau, Bengaluru Wednesday, January 7, 2026, 11:30 Hrs [IST] Biocon Biologics, ...